Liver fat and insulin resistance are independently associated with the -514C>T polymorphism of the hepatic lipase gene

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4238-4243

  Stefan, Norbert ^a,c   Schäfer, Silke ^a   Machicao, Fausto ^a   Machann, Jürgen ^a   Schick, Fritz ^a   Claussen, Claus D ^a   Stumvoll, Michael ^b   Häring, Hans Ulrich ^a   Fritsche, Andreas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Department of Internal Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE; FAT; GLUCOSE; INSULIN; LIVER ENZYME; LIVER TRIACYLGLYCEROL LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BODY FAT; CONTROLLED STUDY; DATA ANALYSIS; FAT CONTENT; FEMALE; GENDER; GENE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NUTRIENT; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LIPASE; LIPID METABOLISM; LIVER; MALE; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 23044471410     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2479     Document Type: Article

References (45)

1. Kahn BB, Flier JS 2000 Obesity and insulin resistance. J Clin Invest 106:473-481
2. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman GI, Caprio S 2003 Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362:951-957
3. Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Jarvinen H 2002 Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 10:59-87
4. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC 2003 Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance: Am J Physiol Endocrinol Metab 285:906-916
5. Danforth Jr E 2000 Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26:13
6. Angulo P 2002 Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
7. Bensadoun A, Berryman DE 1996 Genetics and molecular biology of hepatic lipase. Curr Opin Lipidol 7:77-81
8. Santamarina-Fojo S, Haudenschild C, Amar M 1998 The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9:211-219
9. Guerra R, Wang J, Grundy SM, Cohen JC. Guerra R, Wang J, Grundy SM, Cohen JC 1997 A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 94:4532-4537
10. Despres JP, Ferland M, Moorjani S, Nadeau A, Tremblay A, Lupien PJ, Theriault G, Bouchard C 1989 Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 9:485-492
11. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD 2003 Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 44:1279-1286
12. Jansen H, Verhoeven AJ, Weeks L, Kastelein JJ, Halley DJ, van den Ouweland A, Jukema JW, Seidell JC, Birkenhager JC 1997 Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 17:2837-2842
13. Murtomaki S, Tahvanainen E, Antikainen M, Tiret L, Nicaud V, Jansen H, Ehnholm C 1997 Hepatic lipase gene polymorphisms influence plasma HDL levels. Results from Finnish EARS participants. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 17:1879-1884
14. Deeb SS, Peng R 2000 The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 41:155-158
15. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD 1998 Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 18:1723-1729
16. Tahvanainen E, Syvanne M, Frick MH, Murtomaki-Repo S, Antikainen M, Kesaniemi YA, Kauma H, Pasternak A, Taskinen MR, Ehnholm C 1998 Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 101: 956-960
17. Dugi KA, Brandauer K, Schmidt N, Nau B, Schneider JG, Mentz S, Keiper T, Schaefer JR, Meissner C, Kather H, Bahner ML, Fiehn W, Kreuzer J 2001 Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation 104:3057-3062
18. St-Pierre J, Miller-Felix I, Paradis ME, Bergeron J, Lamarche B, Despres JP, Gaudet D, Vohl MC 2003 Visceral obesity attenuates the effect of the hepatic lipase -514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men. Mol Genet Metab 78:31-36
19. Ordovas JM, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, Wilson PW, Schaefer EJ, Tucker KL 2002 Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 106:2315-2321
20. Tai ES, Corella D, Deurenberg-Yap M, Cutter J, Chew SK, Tan CE, Ordovas JM 2003 Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. J Nutr 133:3399-3408
21. Pihlajamaki J, Karjalainen L, Karhapaa P, Vauhkonen I, Taskinen MR, Deeb SS, Laakso M 2000 G-250A substitution in promoter of hepatic lipase gene is and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 20:1789-1795
22. Jansen H, Waterworth DM, Nicaud V, Ehnholm C, Talmud PJ 2001 EARS-II Study Group. Interaction of the common apolipoprotein C-III (APOC3-482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARSII). Ann Hum Genet 65:237-243
23. Machicao F, Staiger H, Fritsche A, Guirguis A, Weisser M, Stumvoll M, Haring HU 2004 Association of the -514C→T polymorphism in the hepatic lipase gene (LIPC) promoter with elevated fasting insulin concentrations, but not insulin resistance, in non-diabetic Germans. Horm Metab Res 36:303-306
24. Todorova B, Kubaszek A, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M 2004 Finnish Diabetes Prevention Study: the G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89:2019-2023
25. Shuldiner AR, Hoppman N, Pollin TI 2004 Hepatic lipase genotype, diabetes risk, and implications for preventative medicine. J Clin Endocrinol Metab 89:2015-2018
26. Stumvoll M, Haring H 2002 The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 51:2341-2347
27. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
28. Matsuda A, DeFronzo R 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462-1470
29. Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Haring HU 2000 The PPARγ2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32:413-416
30. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA 2004 Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206
31. Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Jarvinen H 2002 Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 10:859-867
32. Thamer C, Machann J, Haap M, Bachmann O, Wietek B, Dahl D, Tschritter O, Fritsche A, Jacob S, Schick F, Stumvoll M, Haring H 2004 Reduced insulin effect in subclinical fatty liver. Dtsch Med Wochenschr 129:872-875
33. Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, Fredriksson J, Yki-Jarvinen H 2004 Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47:1360-1369
34. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP activated protein kinase. Nat Med 8:1288-1295
35. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953
36. Bergman RN, Ader M 2000 Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356
37. Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, Montminy M 2003 CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ. Nature 426:190-193
38. Zambon A, Deeb SS, Bensadoun A, Foster KE, Brunzell JD 2000 In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res 41:2094-2099
39. Haffner SM 2002 Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 90:55i- 61i
40. Dichek HL, Brecht W, Fan J, Ji ZS, McCormick SP, Akeefe H, Conzo L, Sanan DA, Weisgraber KH, Young SG, Taylor JM, Mahley RW 1998 Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake J Biol Chem 273:1896-1903
41. Lonardo A, Loria P 2002 Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 36:514-515
42. Lonardo A, Bellini M, Tartoni P, Tondelli E 1997 The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 29:351-356
43. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ 2001 Evidence for gene-nutrient interaction at the PPARγ locus. Diabetes 50:686-689
44. Li S, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS 2003 The Bogalusa Heart Study: the peroxisome proliferator-activated receptor-γ2 gene polymorphism (Pro12Ala) beneficially influences insulin resistance and its tracking from childhood to adulthood: the Bogalusa Heart Study. Diabetes 52:1265-1269
45. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-Δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812